241 related articles for article (PubMed ID: 37801166)
1. [Treatment-Quo vadis neurodegeneration?].
Vöglein J; Levin J; Höglinger G
Nervenarzt; 2023 Oct; 94(10):904-912. PubMed ID: 37801166
[TBL] [Abstract][Full Text] [Related]
2. Novel Approaches for the Treatment of Alzheimer's and Parkinson's Disease.
Van Bulck M; Sierra-Magro A; Alarcon-Gil J; Perez-Castillo A; Morales-Garcia JA
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30743990
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for neurodegenerative diseases.
Hansson O
Nat Med; 2021 Jun; 27(6):954-963. PubMed ID: 34083813
[TBL] [Abstract][Full Text] [Related]
4. Biosensor approaches on the diagnosis of neurodegenerative diseases: Sensing the past to the future.
Karaboğa MNS; Sezgintürk MK
J Pharm Biomed Anal; 2022 Feb; 209():114479. PubMed ID: 34861607
[TBL] [Abstract][Full Text] [Related]
5. Role of miRNAs in Neurodegeneration: From Disease Cause to Tools of Biomarker Discovery and Therapeutics.
Roy B; Lee E; Li T; Rampersaud M
Genes (Basel); 2022 Feb; 13(3):. PubMed ID: 35327979
[TBL] [Abstract][Full Text] [Related]
6. Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.
Noelker C; Hampel H; Dodel R
Mol Diagn Ther; 2011 Apr; 15(2):83-102. PubMed ID: 21623645
[TBL] [Abstract][Full Text] [Related]
7. The Immune System and Neuroinflammation as Potential Sources of Blood-Based Biomarkers for Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.
Clark LF; Kodadek T
ACS Chem Neurosci; 2016 May; 7(5):520-7. PubMed ID: 27046268
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Neurodegeneration: Integrating Photobiomodulation and Neurofeedback in Alzheimer's Dementia and Parkinson's: A Review.
Berman MH; Nichols TW
Photobiomodul Photomed Laser Surg; 2019 Oct; 37(10):623-634. PubMed ID: 31647776
[No Abstract] [Full Text] [Related]
9. Personalized medicine in neurodegenerative diseases: how far away?
Gotovac K; Hajnšek S; Pašić MB; Pivac N; Borovečki F
Mol Diagn Ther; 2014 Feb; 18(1):17-24. PubMed ID: 24122102
[TBL] [Abstract][Full Text] [Related]
10. Olfactory Dysfunction in Neurodegenerative Diseases.
Marin C; Vilas D; Langdon C; Alobid I; López-Chacón M; Haehner A; Hummel T; Mullol J
Curr Allergy Asthma Rep; 2018 Jun; 18(8):42. PubMed ID: 29904888
[TBL] [Abstract][Full Text] [Related]
11. Role of Long Non-coding RNAs in the Pathogenesis of Alzheimer's and Parkinson's Diseases.
Sivagurunathan N; Ambatt ATS; Calivarathan L
Curr Aging Sci; 2022; 15(2):84-96. PubMed ID: 35081899
[TBL] [Abstract][Full Text] [Related]
12. Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment.
Pathak N; Vimal SK; Tandon I; Agrawal L; Hongyi C; Bhattacharyya S
Metab Brain Dis; 2022 Jan; 37(1):67-104. PubMed ID: 34719771
[TBL] [Abstract][Full Text] [Related]
13. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.
Sengupta U; Kayed R
Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272
[TBL] [Abstract][Full Text] [Related]
14. Translational research on reserve against neurodegenerative disease: consensus report of the International Conference on Cognitive Reserve in the Dementias and the Alzheimer's Association Reserve, Resilience and Protective Factors Professional Interest Area working groups.
Perneczky R; Kempermann G; Korczyn AD; Matthews FE; Ikram MA; Scarmeas N; Chetelat G; Stern Y; Ewers M
BMC Med; 2019 Feb; 17(1):47. PubMed ID: 30808345
[TBL] [Abstract][Full Text] [Related]
15. From Recognition to Remedy: The Significance of Biomarkers in Neurodegenerative Disease Pathology.
Toader C; Dobrin N; Brehar FM; Popa C; Covache-Busuioc RA; Glavan LA; Costin HP; Bratu BG; Corlatescu AD; Popa AA; Ciurea AV
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003309
[TBL] [Abstract][Full Text] [Related]
16. Genetic and Transcriptomic Profiles of Inflammation in Neurodegenerative Diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and Tauopathies.
López González I; Garcia-Esparcia P; Llorens F; Ferrer I
Int J Mol Sci; 2016 Feb; 17(2):206. PubMed ID: 26861289
[TBL] [Abstract][Full Text] [Related]
17. Looking backward to move forward: early detection of neurodegenerative disorders.
DeKosky ST; Marek K
Science; 2003 Oct; 302(5646):830-4. PubMed ID: 14593169
[TBL] [Abstract][Full Text] [Related]
18. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
[TBL] [Abstract][Full Text] [Related]
19. Exosome Biomarkers Revolutionize Preclinical Diagnosis of Neurodegenerative Diseases and Assessment of Treatment Responses in Clinical Trials.
Kapogiannis D
Adv Exp Med Biol; 2020; 1195():149. PubMed ID: 32468469
[TBL] [Abstract][Full Text] [Related]
20. The potential utility of smell testing to screen for neurodegenerative disorders.
Goodwin GR; Bestwick JP; Noyce AJ
Expert Rev Mol Diagn; 2022 Feb; 22(2):139-148. PubMed ID: 35129037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
